Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
BioPharmaceutical Platform Technologies

The Emerging Science of Aging

This article was originally published in Start Up

  • Analysis

Executive Summary

New understanding of genetics and molecular medicine are behind companies targeting diseases of saging (the age when senescene begins)--some caused by geronto-genes.

You may also be interested in...



MRx Biosciences, Inc.

Drug Discovery Tools; Genomics. MRx Biosciences is applying functional genomics to aging. It has licensed a line of fruit flies which have been selectively bred to live longer to use as models for understanding the cellular mechanisms and biochemical pathwaysinvolved in the aging process.

Aeiveos Sciences Group LLC

Drug Discovery Tools; Genomics. Aeiveos is combining genomics and bioinformatics to get a grasp on the science of aging.

Jouvence Pharmaceuticals Inc.

Drug Discovery Tools; Genomics. Jouvence is dedicated to developing anti-aging therapies through genomics efforts. The company has licensed the LAG-1 gene, one of the first genes definitively linked to the longevity of an organism. Yeast strains in which the gene has been knocked out live 100% longer than average.
Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
BioPharmaceutical Platform Technologies
UsernamePublicRestriction

Register

SC089798

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By